RR

Richard Ransohoff

Co-founder and Clinical Advisor at Abata Therapeutics and Venture Partner, Third Rock Ventures

Greater Boston

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Venture Partner

    2019

  • Entrepreneur In Residence

    2018 - 2019

  • Co-founder and Chief Medical Officer

    2021

2014 - 2017

  • VP

    2014 - 2017

    My responsibility at Biogen as VP, and Research/Early Development Unit Head for Neuroimmunology & MS/Pain/Acute Neurology ([NIPAN]; 2014-2017) entailed leading a group of >45 scientists and clinicians in finding and prosecuting neuroinflammatory targets for treatment of neurological disease and pain, and bringing those relevant for acute neurology indications through phase II proof of concept (PoC). During this time, I led the transformation of the neuroinflammation portfolio, successfully bringing 5 compounds (internally developed and externally identified) into the clinic as well as directing activities in blood-brain barrier (BBB) function, progressive multifocal leukoencephalopathy (PML) risk mitigation and novel screening technologies for glial targets, in addition to basic neuroinflammation biology.

  • Member Of Scientific Staff

    1989 - 2014

1984 - 2014

  • Neurologist

    1984 - 2014

    Staff Neurologist, Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic. Named in "Best Doctors" 1996-2014"